Neurimmune Holding Ag

University of Zürich

Biogen International Neuroscience Gmbh

Biogen Ma Inc.

Unversität Zürich

Biogen Idec International Neuroscience Gmbh

Feng Chen

Jan Grimm

Roger Nitsch

Fabrice Heitz

Ioana Combaluzier

Christoph Hock

Jean-Luc Baeriswyl

Ellen A Garber

Paul H Weinreb

Fabio Montrasio

Jürgen Götz

Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.

Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof

Human islet amyloid polypeptide (HIAPP) specific antibodies and uses thereof

Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Human anti-tau antibodies

Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

The present invention discloses a method and an in-vivo assay system useful for the identification and testing of modulating agents as well as for the validation of therapies of neurodegenerative diseases associated with the formation of neurofibrillary tangles, in particular Alzheimer's disease. The present invention is based on the surprising finding that injection of &#x3b2;-amyloid A&#x3b2;fibrils into brains of P301L mutant tau transgenic mice caused several-fold increases in the numbers and an accelerated production of neurofibrillary tangles in cell bodies predominantly within the amygdala. The induced neurofibrillary tangles occurred as early as 18 days after A&#x3b2;injections and displayed striking features of neurofibrillary tangles of several human neurodegenerative diseases, particularly Alzheimer's disease.

Inducing neurofibrillary tangles in transgenic mice expressing a mutant tau protein

Growing community of inventors

Zurich, Switzerland

Feng Chen